ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 95 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $242,641 | +7.6% | 15,396 | +3.5% | 0.00% | – |
| Q4 2023 | $225,447 | -23.2% | 14,881 | +1.6% | 0.00% | – |
| Q3 2023 | $293,679 | -26.1% | 14,640 | +4.0% | 0.00% | – |
| Q2 2023 | $397,225 | +71.3% | 14,081 | +4.5% | 0.00% | – |
| Q1 2023 | $231,821 | -20.1% | 13,478 | -6.4% | 0.00% | – |
| Q4 2022 | $290,016 | +12.8% | 14,400 | +21.1% | 0.00% | – |
| Q3 2022 | $257,000 | -16.0% | 11,891 | +9.3% | 0.00% | – |
| Q2 2022 | $306,000 | -44.1% | 10,880 | -8.3% | 0.00% | – |
| Q1 2022 | $547,000 | -43.7% | 11,862 | +2.6% | 0.00% | -100.0% |
| Q4 2021 | $972,000 | -7.9% | 11,559 | -27.0% | 0.00% | 0.0% |
| Q3 2021 | $1,055,000 | +34.9% | 15,831 | +7.8% | 0.00% | 0.0% |
| Q2 2021 | $782,000 | +205.5% | 14,691 | +148.5% | 0.00% | – |
| Q1 2021 | $256,000 | -28.9% | 5,911 | -14.7% | 0.00% | – |
| Q4 2020 | $360,000 | – | 6,932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
| Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
| Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
| 5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
| Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
| Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
| First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
| Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |